Advertisement
Home »

The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.

Jun 26, 2023

ABOUT THE EXPERTS

  • Meghan J Mooradian

    Division of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

    Harvard Medical School, Boston, Massachusetts, USA.

    Ryan J Sullivan

    Division of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

    Harvard Medical School, Boston, Massachusetts, USA.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement